Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | STK17B | O94768 | 1/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2667029 | 0.77 | CDK2 (0.45) | IDO1TDP1HTTSTK17BSTK17A | |
| SCHEMBL2669089 | 0.77 | CCNE2 (0.45) | IDO1TDP1HTTSTK17BSTK17A | |
| SCHEMBL19274584 | 0.75 | PDPK1 (0.46) | IDO1TDP1HTTSTK17BSTK17A | |
| SCHEMBL20983553 | 0.72 | CCNE2 (0.41) | IDO1TDP1HTTSTK17BSTK17A | |
| SCHEMBL10259122 | 0.72 | NPSR1 (0.43) | IDO1TDP1HTTSTK17BSTK17A | |
| SCHEMBL4612706 | 0.70 | IDO1 (0.46) | IDO1TDP1MEN1KMT2AMALT1 | |
| SCHEMBL10493769 | 0.70 | IDO1 (0.46) | IDO1TDP1HTTLMNAMALT1 | |
| SCHEMBL28195039 | 0.70 | IDO1 (0.41) | IDO1TDP1HTTSTK17BSTK17A | |
| SCHEMBL7528860 | 0.70 | MTNR1A (0.62) | IDO1HTTMEN1KMT2ALMNA | |
| SCHEMBL31490568 | 0.69 | IDO1 (0.48) | IDO1TDP1HTTSTK17BSTK17A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102947311-B | 3-oxo-3, 9-dihydro-1H-benzopyrano [2,3-C ] pyrroles as glucokinase activators | HOFFMAN-LA ROCHE LTD. (CH) | 2015-11-25 | — | — | CN | disclosed |
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8258134-B2 | Pyridazinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8178689-B2 | Tricyclic compounds | HOFFMAN-LA ROCHE INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2274297-B1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | disclosed |
| US-20110313002-A1 | TRICYCLIC COMPOUNDS | SARABU RAMAKANTH (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HAYNES NANCY-ELLEN | 2011-01-27 | — | — | US | disclosed |
| EP-2268633-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-7741327-B2 | Pyrrolidinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127544-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | IDO1 2217/4885TDP1 2582/4885HTT 3606/4885 |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | GCKR, GCK, PDK2 | IDO1 2947/4885TDP1 1793/4885HTT 2401/4885 |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | IDO1 2217/4885TDP1 2582/4885HTT 3606/4885 |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | GCK, GCKR, PDXK | IDO1 3007/4885TDP1 3385/4885HTT 3381/4885 |
| US-20110313002-A1 | TRICYCLIC COMPOUNDS | GPR119, PC, GOT2 | IDO1 2222/4885TDP1 3628/4885HTT 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.